NO.1 PHARMACY(SH:600833) Zheng Quan Zhi Xing·2025-09-04 09:12Core Viewpoint - The legal opinion letter confirms the legality and validity of the procedures, qualifications, proposals, and voting results of the Shanghai First Pharmaceutical Co., Ltd. 2025 Second Extraordinary General Meeting of Shareholders held on September 4, 2025 [1][6]. Group 1: Meeting Summons - The company announced the convening of the 2025 Second Extraordinary General Meeting of Shareholders on August 20, 2025, via the Shanghai Stock Exchange website [3]. - The meeting was scheduled to take place on September 4, 2025, with all necessary details communicated to shareholders 15 days prior [3]. Group 2: Meeting Proceedings - The meeting was held at the designated location, and the voting time was set for the trading hours of September 4, 2025, from 9:15 to 9:25 [3][4]. - Specific voting procedures for margin trading and other related accounts were outlined in accordance with regulatory guidelines [3]. Group 3: Attendance and Voting - A total of 2 shareholders and their representatives attended the meeting, representing 100,854,234 shares with voting rights, which accounted for a significant portion of the total voting shares [4]. - Additionally, 141 shareholders participated in the voting through an online system, with their qualifications verified by the system provider [5]. Group 4: Proposals and Voting Results - The meeting included proposals such as the reappointment of the internal control auditing accounting firm, which were approved by a majority of the voting rights present [5]. - The voting results were announced, confirming that all resolutions passed were in compliance with relevant laws and regulations [5][6]. Group 5: Conclusion - The legal opinion concludes that all aspects of the meeting, including the summons, proceedings, attendance, proposals, and voting, adhered to the applicable laws and the company's articles of association, rendering the resolutions valid [6].